INOVIQ Mapped Pathway for Ovarian Cancer Test
The company has defined a 12-to-18-month commercialization plan for its new diagnostic test in the United States.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should private companies face stricter public oversight when developing new medical diagnostic tests?
INOVIQ has announced a new 12-to-18-month commercialization pathway for its EXO-OC ovarian cancer test following the discontinuation of a verification study. The company intends to launch the diagnostic tool as a laboratory developed test in the United States.
Why it matters
The company decided to discontinue its previous OC2200 verification study after an independent review found that variability in samples collected across five commercial biorepositories made it impossible to reliably assess the test's performance. By shifting to a new validation plan, the company aims to ensure the accuracy and clinical utility of the multi-marker algorithm.
An independent technical review investigated the discontinued OC2200 study, identifying pre-analytical sample collection and handling discrepancies across five biorepositories as the cause of failure. While the test successfully distinguished cancer from benign conditions at a single site, broader reliability was not confirmed.
The players
INOVIQ
A biotechnology company focused on developing diagnostic tests and therapeutics for cancer.
The details
The test utilizes a multi-marker algorithm designed to distinguish ovarian cancer from benign gynecological conditions by identifying specific biological signatures. To overcome previous variability, the company plans to complete a more robust laboratory validation process. This approach relies on the laboratory developed test framework, which allows for diagnostic testing to be performed within a single laboratory environment to ensure consistent sample processing.
Timeline
September 30, 2026: The commercialization pathway announcement was published.
First half of 2028: The company targets the completion of its laboratory validation.
Health Landscape
The transition to a laboratory developed test pathway reflects a common strategic pivot in diagnostic development when multi-site clinical validation encounters technical obstacles. This approach focuses on optimizing standardized testing environments to deliver consistent results for complex oncological biomarkers.
This development indicates that the diagnostic tool remains in the research and validation phase and is not yet available for clinical use. Patients with concerns regarding ovarian cancer screening should continue to discuss established diagnostic options with their physician.
The takeaway
Diagnostic tests often undergo several iterations of validation before they are ready for widespread clinical use. If you are tracking new cancer screening technologies, consult your healthcare provider to understand which tests are currently validated for clinical practice versus those in development.
Further reading
For more information on diagnostic advancements, visit Cancer.
Source note: This article includes information reported by Small Caps.
Live Poll
Should private companies face stricter public oversight when developing new medical diagnostic tests?
